Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 33-41, March 2007

Biochemistry of neuroendocrine tumours

  • Wouter W. de Herder, MD, PhD (Consultant Endocrinologist)

      Affiliations

    • Corresponding Author InformationTel.: +31 10 4635950; Fax: +31 10 4633268.

Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, 's Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands

Several circulating or urinary tumour markers can be used for the diagnosis and follow-up of functioning and clinically non-functioning neuroendocrine tumours of the pancreatic islet cells and intestinal tract. Among the specific tumour markers are serotonin and its metabolites – e.g. 5-hydroxyindoleacetic acid (5-HIAA) – in carcinoid tumours and the carcinoid syndrome, insulin and its precursors or breakdown products in insulinoma, and gastrin in gastrinoma. Plasma vasointestinal polypeptide (VIP) determinations have been used in the diagnosis of VIPoma, plasma glucagon for glucagonoma, and serum somatostatin for somatostatinoma. Among the tumour-non-specific markers are: chromogranins, neuron-specific enolase (NSE), α-subunits of the glycoprotein hormones, catecholamines, pancreatic polypeptide (PP), ghrelin and adrenomedullin.

Key words: serotonin, 5-HIAA, carcinoid, insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, chromogranins, neuron-specific enolase (NSE), α-subunits of the glycoprotein hormones, catecholamines, pancreatic polypeptide (PP), ghrelin, adrenomedullin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(06)00111-4

doi:10.1016/j.beem.2006.12.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 33-41, March 2007